NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols

[1]  R. Ozols,et al.  Mechanisms of drug resistance in ovarian cancer , 2010, Cancer.

[2]  L. Ignarro,et al.  NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and mdulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts , 2008, Cell cycle.

[3]  G. Thatcher,et al.  Quinone formation as a chemoprevention strategy for hybrid drugs: balancing cytotoxicity and cytoprotection. , 2007, Chemical research in toxicology.

[4]  D. Amadori,et al.  Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines , 2007, Journal of Translational Medicine.

[5]  K. Nugent,et al.  Cisplatin Nephrotoxicity: A Review , 2007, The American journal of the medical sciences.

[6]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[7]  K. Kashfi,et al.  The mechanism of action of nitric oxide-donating aspirin. , 2007, Biochemical and biophysical research communications.

[8]  I. D. de Esch,et al.  Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. , 2007, Journal of medicinal chemistry.

[9]  L. Rybak,et al.  Mechanisms of cisplatin-induced ototoxicity and prevention , 2007, Hearing Research.

[10]  B. Aggarwal,et al.  Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. , 2007, Blood.

[11]  M. Dolan,et al.  Molecular mechanisms of resistance and toxicity associated with platinating agents. , 2007, Cancer treatment reviews.

[12]  K. Shailubhai,et al.  Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod , 2007, Molecular Cancer Therapeutics.

[13]  A. Campos-Caro,et al.  Nitric Oxide Decreases Subventricular Zone Stem Cell Proliferation by Inhibition of Epidermal Growth Factor Receptor and Phosphoinositide‐3‐Kinase/Akt Pathway , 2007, Stem cells.

[14]  H. Coley,et al.  Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. , 2006, Biochemical pharmacology.

[15]  D. Bell,et al.  Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer , 2006, Clinical Cancer Research.

[16]  D. Amadori,et al.  Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines* , 2006, Apoptosis.

[17]  Takafumi Yoshida,et al.  Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. , 2006, Cancer research.

[18]  Anna Tesei,et al.  Efficacy of a nitric oxide–releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts , 2006, Molecular Cancer Therapeutics.

[19]  J. Zweier,et al.  Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Amadori,et al.  Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells , 2005, Apoptosis.

[21]  Sheng-Chieh Hsu,et al.  Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. , 2005, Cancer cell.

[22]  C. Woodworth,et al.  Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment , 2005, Molecular Cancer Therapeutics.

[23]  Jianjun Gao,et al.  In Vitro Metabolism of Nitric Oxide-Donating Aspirin: The Effect of Positional Isomerism , 2005, Journal of Pharmacology and Experimental Therapeutics.

[24]  Francesca Benedini,et al.  Positional Isomerism Markedly Affects the Growth Inhibition of Colon Cancer Cells by Nitric Oxide-Donating Aspirin in Vitro and in Vivo , 2005, Journal of Pharmacology and Experimental Therapeutics.

[25]  D. Amadori,et al.  In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines , 2005, Journal of Translational Medicine.

[26]  Petra Schmalbrock,et al.  In vivo measurement and imaging of tumor oxygenation using coembedded paramagnetic particulates , 2004, Magnetic resonance in medicine.

[27]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[28]  V. Diéras,et al.  The taxanes: toxicity and quality of life considerations in advanced ovarian cancer , 2003, British Journal of Cancer.

[29]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[30]  C. Rudin,et al.  Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. , 2003, Cancer research.

[31]  M. Gore,et al.  Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. , 2002, The Lancet. Oncology.

[32]  M. Gore,et al.  Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. , 2002, The Lancet. Oncology.

[33]  A. Hall,et al.  Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer. , 2002, Gynecologic oncology.

[34]  J. Essigmann,et al.  Mechanisms of resistance to cisplatin. , 2001, Mutation research.

[35]  G. Hoffmann,et al.  Nitric oxide-dependent apoptosis in ovarian carcinoma cell lines. , 2001, Gynecologic oncology.

[36]  S. Gansauge,et al.  Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells , 2000, Cancer.

[37]  B. Trock,et al.  Prognostic Value of p53, Glutathione S-Transferase π, and Thymidylate Synthase for Neoadjuvant Cisplatin-based Chemotherapy in Head and Neck Cancer , 1999 .

[38]  M. McKeage,et al.  Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. , 1999, Journal of inorganic biochemistry.

[39]  R. Sorrentino,et al.  NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. , 1999, Trends in pharmacological sciences.

[40]  B. Trock,et al.  Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer. , 1998, Chemico-biological interactions.

[41]  James B. Mitchell,et al.  In vivo electron paramagnetic resonance imaging of tumor heterogeneity and oxygenation in a murine model. , 1998, Cancer research.

[42]  V. Reznikov,et al.  Quantitative determination and reversible modification of thiols using imidazolidine biradical disulfide label. , 1997, Journal of biochemical and biophysical methods.

[43]  E. Montgomery,et al.  Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  J. Zweier,et al.  Spatial mapping of nitric oxide generation in the ischemic heart using electron paramagnetic resonance imaging , 1996, Magnetic resonance in medicine.

[45]  R. Schirmer,et al.  Inhibition of human glutathione reductase by S-nitrosoglutathione. , 1995, European journal of biochemistry.

[46]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[47]  S. Abramson,et al.  Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: evidence for S-nitrosoglutathione as a bioactive intermediary. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Z. Oltvai,et al.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.

[49]  M. Jones,et al.  In vivo spin trapping of nitric oxide in mice. , 1993, Biochemical and biophysical research communications.

[50]  S. Hahn,et al.  Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. , 1993, Cancer research.

[51]  T. Ishikawa,et al.  The ATP-dependent glutathione S-conjugate export pump. , 1992, Trends in biochemical sciences.

[52]  L. Weiner,et al.  Quantitative determination of SH groups in low- and high-molecular-weight compounds by an electron spin resonance method. , 1989, Analytical biochemistry.

[53]  A. Clark,et al.  Inhibition of glutathione S-transferases from rat liver by S-nitroso-L-glutathione. , 1988, Biochemical pharmacology.

[54]  A. Eastman.  Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. , 1987, Chemico-biological interactions.

[55]  Seth M. Cohen,et al.  Cisplatin: from DNA damage to cancer chemotherapy. , 2001, Progress in nucleic acid research and molecular biology.

[56]  B. Trock,et al.  Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  S. Howell,et al.  Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. , 1990, Cancer communications.

[58]  D. Kern,et al.  In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). , 1988, Cancer research.